YAMADIN Tablet

1) Short term treatment of active duodenal ulcer and benign gastric ulcer

2) Maintenance therapy for prevention of relapses of duodenal ulceration

3) Gastro-oesophageal reflux disease

4) Zollinger-Ellison Syndrome

Dosage and Administration

1) Duodenal ulcer: 40mg at night for 4-8 weeks

2) Benign gastric ulcer: 40mg at night for 4-8 weeks

3) Maintenance therapy: 20mg at night for preventing the recurrences of duodenal ulceration

4) Gastro-oesophageal reflux disease: 20mg twice daily for 6-12 weeks

5) Zollinger-Ellison Syndrome: The recommended starting dose is 20mg every 6 hours. Dosage should then be adjusted to individual response. Doses up to 160mg every 6 hours have been administered to some patients without the development of significant adverse effects.

Dosage can be administered irrespective of meals. Antacids may be given concomitantly if needed.

There are no known contraindications to Yamadin. If any evidence of hypersensitivity appears, discontinue the therapy and consult your physician.

Dizziness, headache, constipation and diarrhoea have been reported rarely. Other side effects reported less frequently include dry mouth, nausea and/or vomiting, rash, abdominal discomfort, anorexia and fatigue.

Yamadin does not interact with the CYP450 linked drug metabolizing enzyme system. So, no interactions have been found in man with warfarin, theophylline, phenytoin, diazepam, propranolol, aminopyridine or antipyrine.

Pregnancy

There are no adequate, well-controlled studies on Famotidine in pregnancy, but it is known to cross the placenta and should be prescribed only if clearly needed.

Nursing mothers

It is not known whether Famotidine is secreted into human milk. Nursing mothers should either stop nursing or stop taking the drug.

Impaired renal function: Dosage reduction should be considered or interval between doses should be prolonged if creatinine clearance falls to or below 30mL/min.

Famotidine is a potent inhibitor of gastric acid secretion acting at the H2 receptor site. It is a competitive antagonist with high selectivity and binding affinity. In conscious drugs, famotidine is 40 times as potent as cimetidine with a duration of action 1-3 times as long. Famotidine has 7-10 times the potency of ranitidine. The affinity of famotidine for the H2 receptor on mouse oxyntic cells is significantly greater than those of ranitidine or cimetidine. Famotidine has no anti-androgenic activity and has no effects on hepatic cytochrome P450 activity.